Prospective Grant of Exclusive License: Diagnostics of Fungal Infections, 53105 [E6-14872]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 174 / Friday, September 8, 2006 / Notices
Control and Prevention (CDC),
Technology Transfer Office, Department
of Health and Human Services (DHHS),
is contemplating the grant of a limited
field of use, exclusive license in India
to practice the inventions embodied in
the patent referred to below to
Molecular Diagnostic Laboratory, having
a place of business in Lucknow, India.
The patent rights in these inventions
have been assigned to the government of
the United States of America. The
patent(s) to be licensed are:
US 6,896,892 B2 entitled ‘‘InsecticideImpregnated Fabric and Method of
Production,’’ issue date 05.24.2005. CDC
Technology ID No. I–008–99.
Status: Issued.
Issue Date: 05.24.2005
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7.
Technology: This technology provides
a new insecticide-impregnated fabric
and method of production for bednets.
In
accordance with 35 U.S.C. 209(e) and 37
CFR 404.7(a)(1)(i), CDC is providing
public notice of its intention to grant an
exclusive license. CDC will accept
written comments concerning this
notice for 30 days. Applications for a
license filed in response to this notice
will be treated as objections to the grant
of the contemplated license. Only
written comments and/or applications
for a license which are received by CDC
within thirty days of this notice will be
considered. Comments and objections
submitted in response to this notice will
not be made available for public
inspection, and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
SUPPLEMENTARY INFORMATION:
Requests for a copy of this
patent, inquiries, comments, and other
materials relating to the contemplated
license should be directed to Suzanne
Seavello Shope, J.D., Technology
Licensing and Marketing Specialist,
Technology Transfer Office, Centers for
Disease Control and Prevention (CDC),
4770 Buford Highway, Mailstop K–79,
Atlanta, GA 30341, telephone: (770)
488–8613; facsimile: (770) 488–8615.
sroberts on PROD1PC70 with NOTICES
ADDRESSES:
Dated: August 31, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease
Control and Prevention.
[FR Doc. E6–14871 Filed 9–7–06; 8:45 am]
BILLING CODE 4163–18–P
VerDate Aug<31>2005
19:38 Sep 07, 2006
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Prospective Grant of Exclusive
License: Diagnostics of Fungal
Infections
Technology Transfer Office,
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services.
ACTION: Notice.
AGENCY:
SUMMARY: This is a notice in accordance
with 35 U.S.C. 209(e) and 37 CFR
404.7(a)(1)(i) that the Centers for Disease
Control and Prevention (CDC),
Technology Transfer Office, Department
of Health and Human Services (DHHS),
is contemplating the grant of a
worldwide, limited field of use, coexclusive license to practice the
inventions embodied in the patent and
patent applications referred to below to
Myconostica, Inc. (Myconostica) having
a place of business in Manchester,
United Kingdom. CDC intends to grant
no more than three licenses to these
inventions. The patent rights in these
inventions have been assigned to the
government of the United States of
America. The patent and patent
applications to be licensed are:
Title: Nucleic Acids for Detecting
Aspergillus Species and Other
Filamentous Fungi.
U.S. Patent Application Serial No.:
09/423,233.
Filing Date: 6/27/2000.
Domestic Status: 6,372,430.
Issue Date: 4/16/2002.
Title: Molecular Identification of
Aspergillus Species.
U.S. Patent Application Serial No.:
60/381,463.
Filing Date: 5/17/2002.
Domestic Status: Pending.
Issue Date: N/A.
Title: Nucleic Acids for the
Identification of Fungi and Methods for
Using the Same.
U.S. Patent Application Serial No.:
60/325,241.
Filing Date: 9/26/2001.
Domestic Status: Pending.
Issue Date: N/A.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7.
Specific DNA (oligonucleotide)
probes have been developed for a wide
variety of systemic disease causing
fungi, including Aspergillus species and
others. A probe has been developed for
identification of all dimorphic fungi.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
53105
These probes can be used for the rapid
identification of fungal pathogens and
for the diagnosis of mycotic diseases.
ADDRESSES: Requests for a copy of these
patent applications, inquiries,
comments, and other materials relating
to the contemplated license should be
directed to Andrew Watkins, Director,
Technology Transfer Office, Centers for
Disease Control and Prevention (CDC),
4770 Buford Highway, Mailstop K–79,
Atlanta, GA 30341, telephone: (770)
488–8610; facsimile: (770) 488–8615.
Applications for a license filed in
response to this notice will be treated as
objections to the grant of the
contemplated license. Only written
comments and/or applications for a
license which are received by CDC
within sixty days of this notice will be
considered. Comments and objections
submitted in response to this notice will
not be made available for public
inspection, and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552. A signed Confidential Disclosure
Agreement will be required to receive a
copy of any pending patent application.
Dated: August 31, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease
Control and Prevention.
[FR Doc. E6–14872 Filed 9–7–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0349]
Risk Communication on Medical
Devices: Sharing Perspectives
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public meeting.
SUMMARY: The Food and Drug
Administration (FDA), in cooperation
with the Advanced Medical Technology
Association (AdvaMed), is announcing a
public meeting entitled ‘‘Risk
Communication on Medical Devices:
Sharing Perspectives.’’ This 1-day
workshop is intended to bring together
various creators and recipients of
medical device risk/benefit information
to discuss how this information is
developed, disseminated, and
perceived; and to explore ways in which
the process might be improved.
DATES AND TIMES: The public meeting
will be held on September 26, 2006,
from 7:30 a.m. to 5 p.m. Online
registration is available until 5 p.m. on
E:\FR\FM\08SEN1.SGM
08SEN1
]]>Agencies
[Federal Register Volume 71, Number 174 (Friday, September 8, 2006)]
[Notices]
[Page 53105]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-14872]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Prospective Grant of Exclusive License: Diagnostics of Fungal
Infections
AGENCY: Technology Transfer Office, Centers for Disease Control and
Prevention (CDC), Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention
(CDC), Technology Transfer Office, Department of Health and Human
Services (DHHS), is contemplating the grant of a worldwide, limited
field of use, co-exclusive license to practice the inventions embodied
in the patent and patent applications referred to below to Myconostica,
Inc. (Myconostica) having a place of business in Manchester, United
Kingdom. CDC intends to grant no more than three licenses to these
inventions. The patent rights in these inventions have been assigned to
the government of the United States of America. The patent and patent
applications to be licensed are:
Title: Nucleic Acids for Detecting Aspergillus Species and Other
Filamentous Fungi.
U.S. Patent Application Serial No.: 09/423,233.
Filing Date: 6/27/2000.
Domestic Status: 6,372,430.
Issue Date: 4/16/2002.
Title: Molecular Identification of Aspergillus Species.
U.S. Patent Application Serial No.: 60/381,463.
Filing Date: 5/17/2002.
Domestic Status: Pending.
Issue Date: N/A.
Title: Nucleic Acids for the Identification of Fungi and Methods
for Using the Same.
U.S. Patent Application Serial No.: 60/325,241.
Filing Date: 9/26/2001.
Domestic Status: Pending.
Issue Date: N/A.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
Specific DNA (oligonucleotide) probes have been developed for a
wide variety of systemic disease causing fungi, including Aspergillus
species and others. A probe has been developed for identification of
all dimorphic fungi. These probes can be used for the rapid
identification of fungal pathogens and for the diagnosis of mycotic
diseases.
ADDRESSES: Requests for a copy of these patent applications, inquiries,
comments, and other materials relating to the contemplated license
should be directed to Andrew Watkins, Director, Technology Transfer
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610;
facsimile: (770) 488-8615. Applications for a license filed in response
to this notice will be treated as objections to the grant of the
contemplated license. Only written comments and/or applications for a
license which are received by CDC within sixty days of this notice will
be considered. Comments and objections submitted in response to this
notice will not be made available for public inspection, and, to the
extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552. A signed Confidential Disclosure
Agreement will be required to receive a copy of any pending patent
application.
Dated: August 31, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E6-14872 Filed 9-7-06; 8:45 am]
BILLING CODE 4163-18-P
